Recognizing these issues, along with the potential role of TLR4 as a novel therapeutic target [13,20,37], we conducted a systematic review and meta-analysis of the literature on the basal expression and activation of TLR4 in peripheral blood mononuclear cells (PBMCs) in individuals with schizophrenia. This evidence concerns the gene TLR4 and schizophrenia.